about
Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents.Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structuresMutations in SLC12A5 in epilepsy of infancy with migrating focal seizures.Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long durDopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood.Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental studyInteraction of cocaine-, benztropine-, and GBR12909-like compounds with wild-type and mutant human dopamine transporters: molecular features that differentially determine antagonist-binding properties.Dopamine transporter oligomerization: impact of combining protomers with differential cocaine analog binding affinitiesThe novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents.Synthesis and biological characterization of (3R,4R)-4-(2-(benzhydryloxy)ethyl)-1-((R)-2-hydroxy-2-phenylethyl)-piperidin-3-ol and its stereoisomers for activity toward monoamine transporters.Importance of cholesterol in dopamine transporter function.The importance of company: Na+ and Cl- influence substrate interaction with SLC6 transporters and other proteins.Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an exocyclic hydroxyl group: interaction with dopamine, serotonin, and norepinephrine transporters.Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D₂ and D₃ ReceptorsStructural exploration of (3S,6S)-6-benzhydryl-N-benzyltetrahydro-2H-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressantsHomozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia.Substrate and drug binding sites in LeuT.Effects of diet and insulin on dopamine transporter activity and expression in rat caudate-putamen, nucleus accumbens, and midbrain.Impact of disruption of secondary binding site S2 on dopamine transporter function.Characterization of [³H]CFT binding to the norepinephrine transporter suggests that binding of CFT and nisoxetine is not mutually exclusive.Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding interaction for GBR12909 and benztropine as opposed to cocaine.Structural requirements for 2,4- and 3,6-disubstituted pyran biomimetics of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine compounds to interact with monoamine transporters.Chronic food restriction and dopamine transporter function in rat striatum.Latch and trigger role for R445 in DAT transport explains molecular basis of DTDS.Functional properties of dopamine transporter oligomers after copper linking.Dopamine transporter phosphorylation site threonine 53 is stimulated by amphetamines and regulates dopamine transport, efflux, and cocaine analog binding.Use of radiolabeled antagonist assays for assessing agonism at D2 and D3 dopamine receptors: comparison with functional GTPγS assays.PCSK9 in cholesterol metabolism: from bench to bedsideTamoxifen Directly Interacts with the Dopamine TransporterHuman Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy
P50
Q24603864-59A17FCF-1284-490D-A258-87B172EA0067Q24655640-7FB49F8E-4820-40B5-BB0B-9699FB6781D5Q28116136-7B1BB552-ED0B-4907-89BD-BB147961A9F8Q28260663-D799D97F-6B3C-4DB5-8CF8-9856D8BE138EQ30574381-2F095986-A7EE-48C9-82F8-A56D4211E03FQ34408564-40E2C70E-DF7C-4B29-9AE9-5FF9895B168BQ34825605-AF60EF05-6CCA-478B-A1ED-24A90020F47EQ35371135-0F1C8564-9521-47F2-850A-7F7E85473A9AQ35532003-922C3A0C-2890-4FC0-A638-5E80B2729C18Q36453107-9C90A644-EFFC-4440-B584-328F4F65E45AQ36453517-F18894DC-F904-4758-84A7-E3F78E717518Q36487923-B24C92FD-E9CF-4527-997C-BB25D668FAFFQ36596750-A5E407FA-6A4F-497E-812B-791287E2C536Q36642828-3C82E1CE-565B-49A1-BADC-A95A4BE688FEQ37071538-D8CA8918-8DD6-421E-86E1-109635737ACBQ37209217-800CEC28-FAB0-446F-9C62-EACD695D01FCQ37782457-87A97723-5A0C-448B-B977-7E021F8316C4Q38289781-1C425A11-2695-4AEE-BEED-515B9956B024Q38868543-CE018530-3698-49B6-8EE0-157670B4A424Q39293366-DE1E678D-0076-4C94-8650-0AB321BFF0E1Q40556741-779A9A8D-3EFA-4EF9-ABE2-6C1611C47866Q42170589-DB23A0C9-92B0-44D5-B615-DBDBC35D2256Q46974647-E3847512-E254-49C9-965C-3B0BAD074BDDQ47273983-EC1D0D97-2E51-4E74-A4D0-45716C255D23Q47423929-811E9A41-CFAC-4CDD-9996-23CACDEA17AFQ47758420-9182330E-2135-40DD-A763-9D24B51AA2C5Q48086522-B31A7C49-22A9-4456-88F0-6D5AAA6387FEQ89080708-380065A3-4AA6-444B-8496-08061B8603EEQ90946619-34FF066D-5B92-4FDA-8504-B8F894E52F7FQ92783907-83818416-AE6C-41D3-B1DC-B5BF11E98B7F
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Juan Zhen
@ast
Juan Zhen
@en
Juan Zhen
@es
Juan Zhen
@nl
type
label
Juan Zhen
@ast
Juan Zhen
@en
Juan Zhen
@es
Juan Zhen
@nl
prefLabel
Juan Zhen
@ast
Juan Zhen
@en
Juan Zhen
@es
Juan Zhen
@nl
P106
P21
P31
P496
0000-0002-6111-9692